Predictive Value of Systemic Immune-inflammation Index in Determining Mortality in COVID-19 Patients Cover

.blurhash-client-img { display: none !important; }

Predictive Value of Systemic Immune-inflammation Index in Determining Mortality in COVID-19 Patients

The Journal of Critical Care Medicine

Volume 8 (2022): Issue 3 (July 2022)

By: Tahsin Karaaslan and Esra Karaaslan

Open Access

|Aug 2022

Figures & Tables

ROC curve analysis to test diagnostic ability of SII index for mortality. SII index: systemic immune-inflammation index, ROC: receiver operating characteristic curve; AUC: area under the curve.

ROC curve analysis to test diagnostic ability of NLR for mortalityNLR: neutrophil-to-lymphocyte ratio; ROC: receiver operating characteristic curve; AUC: area under the curve.

Demographic characteristics and clinical and radiological findings of the patients_

		N	Mean			Value	p
Age (year)	Total	191	54,32±17,95	min= 20,	max: 95
	Survivor	156	50,10±15,76	min= 20,	max: 93	t= -7,88	<0,001
	Non-survivor	35	73,11±14,94	min= 23,	max: 95
		N	%	Mortality
Sex	Female	97	50.8%	n=18	18.6%
	Male	94	49.2%	n=17	18.1%	χ2=0,007	0,933

Center	First center	126	66.0%	n=32	25.4%
	Second center	65	34.0%	n=3	4.6%	χ2=12,37	<0,001

Symptoms	Yes	183	95.8%	n=35	19.1%		0,355*
	No	8	4.2%	n=0	0.0%

Fever	Yes	135	70.7%	survivor	n=111; 71.2%
	No	56	29.3%	non-survivor	n=24; 68.6%	χ2=0,092	0,762

Cough	Yes	117	61.3%	survivor	n=95; 60.9%
	No	74	38.7%	non-survivor	n=22; 62.9%	χ2=0,046	0,830

Fatigue	Yes	108	56.5%	survivor	n=87; 55.8%
	No	83	43.5%	non-survivor	n=21; 60.0%	χ2=0,208	0,648

Dyspnea	Yes	64	33.5%	survivor	n= 40; 25.6%	χ2=23,65	<0,001
	No	127	66.5%	non-survivor	n= 24; 68.6%

Myalgia	Yes	53	27.7%	survivor	n= 48; 30.8%
	No	138	72.3%	non-survivor	n=5; 14.3%	χ2=3,87	0,049

Diarrhea	Yes	31	16.2%	survivor	n=25; 16.0%
	No	160	83.8%	non-survivor	n=6; 17.1%	χ2=0,026	0,871

Loss of taste	Yes	16	8.4%	survivor	n=13; 8.3%	χ2=0,02	0,963
and smell	No	175	91.6%	non-survivor	n=3; 8.6%

Thoracic CT	Positive	168	88.0%	Mortality	20.3%		0,009*
scan	Negative	23	12.0%	Mortality	0.0%
	Ground-opacity glass	164	85.9%	Mortality n=33	20.1%	χ2=2,50	0,114
	Consolidation	68	35.6%	Mortality n=20	29.4%	χ2=8,67	0,003

Complete blood count and hematological parameters

	Total median/ min-max	Survivor (median)	Non-survivor (median)		N	%	Mortality rate (%)	U	p
WBC	6000	6000	5700	<4500	41	21.5		2580,0	0,612
(x106/L)	(1500-19000)			4500-10500	135	70.7
				>10500	15	7.8

Lymphocyte	1200	1355	700	<1000	77	40,3		988,0	<0,001
(x106/L)	(200-3600)			>1001	114	59,7

Neutrophil	3970	3835,0	4750,0					1942,5	0,008
(x106/L)	(290-16260)

Eosinophil	10,0	20,0	10,0					2042,0	0,018
(x106/L)	(0,00-640,0)
	Total (median)	Survivor (median)	Non-survivor (median)	Cut-off	Total N	%

Hemoglobin	13,3	13,55	10,90					871,0	<0,001
(g/dL)	(5,7-17,4)

PLT	178,0	178,0	178,0					2639,5	0,759
(x109/L)	(14-653)

RDW	13,5	13,46	15,14					1458,0	<0,001
(%)	(2,6-24,0)	(±1,56)	(±2,43)

SII-Index	585,96	495,52	1477,78	<618,8	103	53.9	6.8%	1357,0	<0,001
	(27,84-15062,5)			>618,9	88	46.1	31.8%

NLR	3,31	2,73	9,27	<4,21	123	64.4	6.5%	1038,5	<0,001
	(0,29-43,8)			>4,21	68	35.6	39.7%

PLR	151,46	139,94	287,5	<189,5	132	69.1	6.1%	1144,0	<0,001
	(16,09-1425,0)			>189,6	59	30.9	45.8%

Comorbidities of patients

	N	%			Value	p
AKI	31	16.2 %	survivor	n=16; 10.3%	χ2=22,35	<0,001
			non-survivor	n=15; 42.9%

Renal Tx	6	3.1 %	survivor	n=5; 3.2%		1,000
			non-survivor	n=1; 2.9%		(Fisher’s)

CKD	28	14.7 %	survivor	n=10; 6.4%	χ2=46,31	<0,001
			non-survivor	n=18; 51.4%

Hypertension	72	37.7 %	survivor	n= 42; 26.9%	χ2=42,07	<0,001
			non-survivor	n= 30; 85.7%

Diabetes	44	23.0 %	survivor	n= 26; 16.7%	χ2=19,48	<0,001
			non-survivor	n= 18; 51.4%

Heart failure	15	7.9 %	survivor	n= 7; 4,5%	χ2=13,33	<0,001
			non-survivor	n= 8; 22,9%
	median	Min.-max.	median		U	p
Creatinine	0,88	0,44-15,36	survivor	0,825	1230,5	<0,001
(mg/dL)			non-survivor	1,52

eGFR (CKD-Epi)	88,13	3,02-133,44	survivor	94,19	808,5	<0,001
(ml/dk)			non-survivor	41,74

LDH	343,0	155-25000	survivor	284,0	779,5	<0,001
(U/L)			non-survivor	408,0

CRP	9,81	0,36-35,25	survivor	5,80	856,5	<0,001
(mg/dL)			non-survivor	12,54

Ferritin	538	9-40000	survivor	192,0	345,5	<0,001
(ng/mL)			non-survivor	861,0

D-Dimer	1130	0,52-6160	survivor	880,0	1095,0	0,252
(ng/mL)			non-survivor	1575,0

Troponin-I	22,9	10-932	survivor	10,0	466,0	<0,001
(ng/mL)			non-survivor	44,8

Procalcitonin	0,13	0,05-28,34	survivor	0,05	299,5	<0,001
(ng/mL)			non-survivor	0,62

DOI: https://doi.org/10.2478/jccm-2022-0013 | Journal eISSN: 2393-1817 | Journal ISSN: 2393-1809

Journal RSS Feed

Language: English

Page range: 156 - 164

Submitted on: Oct 31, 2021

|

Accepted on: Jun 1, 2022

|

Published on: Aug 12, 2022

Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

systemic immune-inflammation index,

neutrophil/lymphocyte ratio,

inflammatory markers

Related subjects:

Clinical medicine,

Internal medicine,

Internal medicine, other,

Surgery, other,

Anaesthesiology,

Emergency medicine and intensive-care medicine

© 2022 Tahsin Karaaslan, Esra Karaaslan, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous article Volume 8 (2022): Issue 3 (July 2022)Next article